Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [22]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11435-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11435-1-AP, RRID:AB_2085739
- Product name
- CRBN antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated CRBN antibody (Cat. #11435-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
Proteomic profiling of centrosomes across multiple mammalian cell and tissue types by an affinity capture method.
Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy.
Endoplasmic Reticulum Stress-Mediated p62 Downregulation Inhibits Apoptosis via c-Jun Upregulation.
Antitumor effect of lenalidomide in malignant glioma cell lines.
CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
AMPK is down-regulated by the CRL4A-CRBN axis through the polyubiquitination of AMPKα isoforms.
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun.
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation.
Cereblon is expressed in the retina and binds to voltage-gated chloride channels.
Lin Z, Zhang Y, Liu X, Luo H, Li Q, Gao Q, Wang X, Wen J, Li L, Feng Y, Wang F, Huang J, Zhai X, Zhang L, Niu T, Zheng Y
British journal of haematology 2024 Aug;205(2):594-606
British journal of haematology 2024 Aug;205(2):594-606
Proteomic profiling of centrosomes across multiple mammalian cell and tissue types by an affinity capture method.
Carden S, Vitiello E, Rosa E Silva I, Holder J, Quarantotti V, Kishore K, Roamio Franklin VN, D'Santos C, Ochi T, van Breugel M, Gergely F
Developmental cell 2023 Nov 6;58(21):2393-2410.e9
Developmental cell 2023 Nov 6;58(21):2393-2410.e9
Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy.
Silva MC, Nandi G, Donovan KA, Cai Q, Berry BC, Nowak RP, Fischer ES, Gray NS, Ferguson FM, Haggarty SJ
Frontiers in cellular neuroscience 2022;16:801179
Frontiers in cellular neuroscience 2022;16:801179
Endoplasmic Reticulum Stress-Mediated p62 Downregulation Inhibits Apoptosis via c-Jun Upregulation.
Yu W, Wang B, Zhou L, Xu G
Biomolecules & therapeutics 2021 Mar 1;29(2):195-204
Biomolecules & therapeutics 2021 Mar 1;29(2):195-204
Antitumor effect of lenalidomide in malignant glioma cell lines.
Hanashima Y, Sano E, Sumi K, Ozawa Y, Yagi C, Tatsuoka J, Yoshimura S, Yamamuro S, Ueda T, Nakayama T, Hara H, Yoshino A
Oncology reports 2020 May;43(5):1580-1590
Oncology reports 2020 May;43(5):1580-1590
CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
Fu SJ, Hu MC, Peng YJ, Fang HY, Hsiao CT, Chen TY, Jeng CJ, Tang CY
Cells 2020 May 26;9(6)
Cells 2020 May 26;9(6)
AMPK is down-regulated by the CRL4A-CRBN axis through the polyubiquitination of AMPKα isoforms.
Kwon E, Li X, Deng Y, Chang HW, Kim DY
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019 May;33(5):6539-6550
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019 May;33(5):6539-6550
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.
Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D, Zhang T, Huang HT, Lucente DE, Dickerson BC, Mitchison TJ, Fischer ES, Gray NS, Haggarty SJ
eLife 2019 Mar 25;8
eLife 2019 Mar 25;8
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C, Dissing Sjö L, Ralfkiaer E, Gimsing P, Grønbaek K
Leukemia & lymphoma 2019 Jan;60(1):180-188
Leukemia & lymphoma 2019 Jan;60(1):180-188
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA
eLife 2018 Nov 15;7
eLife 2018 Nov 15;7
Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun.
Yang J, Huang M, Zhou L, He X, Jiang X, Zhang Y, Xu G
The Journal of biological chemistry 2018 Jun 29;293(26):10141-10157
The Journal of biological chemistry 2018 Jun 29;293(26):10141-10157
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B, Simonitsch-Klupp I, Kornauth C, Dolak W, Lukas J, Mayerhoefer ME, Raderer M
Hematological oncology 2018 Feb;36(1):62-67
Hematological oncology 2018 Feb;36(1):62-67
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C, Hughes SJ, Testa A, Chen W, Lamont DJ, Rocha S, Alessi DR, Romeo R, Ciulli A
Nature communications 2017 Oct 10;8(1):830
Nature communications 2017 Oct 10;8(1):830
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE
Molecular cell 2017 Jul 6;67(1):5-18.e19
Molecular cell 2017 Jul 6;67(1):5-18.e19
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
Ren Y, Wang M, Couto S, Hansel DE, Miller K, Lopez-Girona A, Bjorklund CC, Gandhi AK, Thakurta A, Chopra R, Breider M
Applied immunohistochemistry & molecular morphology : AIMM 2016 Nov Dec;24(10):695-702
Applied immunohistochemistry & molecular morphology : AIMM 2016 Nov Dec;24(10):695-702
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE
Science (New York, N.Y.) 2015 Jun 19;348(6241):1376-81
Science (New York, N.Y.) 2015 Jun 19;348(6241):1376-81
The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.
Shortt J, Hsu AK, Martin BP, Doggett K, Matthews GM, Doyle MA, Ellul J, Jockel TE, Andrews DM, Hogg SJ, Reitsma A, Faulkner D, Bergsagel PL, Chesi M, Heath JK, Denny WA, Thompson PE, Neeson PJ, Ritchie DS, McArthur GA, Johnstone RW
Cell reports 2014 May 22;7(4):1009-19
Cell reports 2014 May 22;7(4):1009-19
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K, Gaidarova S, Ren Y, Wang M, Breider M, Carmel G, Mahmoudi A, Jackson P, Abbasian M, Cathers BE, Schafer PH, Daniel TO, Lopez-Girona A, Thakurta A, Chopra R
British journal of haematology 2014 Jan;164(2):233-44
British journal of haematology 2014 Jan;164(2):233-44
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY, Lin CW, Lin HH, Yao M, Tang JL, Wu SJ, Chen YC, Lu HY, Hou HA, Chen CY, Chou WC, Tsay W, Chou SJ, Tien HF
Annals of hematology 2014 Aug;93(8):1371-80
Annals of hematology 2014 Aug;93(8):1371-80
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg AJ, Walters DK, Kumar SK, Rajkumar SV, Jelinek DF
European journal of haematology 2013 Dec;91(6):504-13
European journal of haematology 2013 Dec;91(6):504-13
Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation.
Lee KJ, Lee KM, Jo S, Kang KW, Park CS
Biochemical and biophysical research communications 2010 Sep 3;399(4):711-5
Biochemical and biophysical research communications 2010 Sep 3;399(4):711-5
Cereblon is expressed in the retina and binds to voltage-gated chloride channels.
Hohberger B, Enz R
FEBS letters 2009 Feb 18;583(4):633-7
FEBS letters 2009 Feb 18;583(4):633-7
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse heart tissue were subjected to SDS PAGE followed by western blot with 11435-1-AP(CRBN antibody) at dilution of 1:1000
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The CRBN antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human CRBN. This antibody recognizes human,mouse,rat antigen. The CRBN antibody has been validated for the following applications: ELISA, WB, IHC analysis.
